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Purpose of the study
The SMART trial showed an increased risk of clinical
events not-AIDS related in a large cohort of HIV-infected
adults after antiretroviral treatment (ARV) interruption.
Many of these events (cardiovascular, liver and kidney dis-
eases) are associated with inflammation, immune activa-
tion and impaired fibrinolysis. A recent analysis showed
that the increase of D-dimer, a marker of thrombosis,
together with the elevation of other inflammatory mark-
ers, are related to the suspension of ARV and the conse-
quent increase of HIV viral load; moreover, it showed an
huge association between D-dimer levels and the risk of
death [1].
HIV-infected children and adolescents, typically with peri-
natal transmission of the infection, have a long story of
viral replication and could develop the same non-AIDS
related alterations demonstrated in adults (metabolic syn-
drome or carotid intima medial thickness) associated with
cardiovascular events. The aim of our study was to inves-
tigate in an HIV-infected pediatric population the preva-
lence and risk factors for the alterations of coagulation
activation markers.
Methods
We performed a cross-sectional study among the cohort
followed at Bambin Gesù Children's Hospital of Rome:
between December 2007 and June 2008 we assessed for
each patient D-dimer levels together with other coagula-
tion and inflammation markers (antithrombin, protein C
anticoagulant, protein S anticoagulant, C-reactive pro-
tein), and their relation with HIV-RNA load, CD4 count,
clinical CDC classification, and current antiretroviral
treatment. Patients with HBV or HCV co-infection were
excluded.
Summary of results
Eighty-eight patients (59.1% females; 86.4% on cART)
ranging from 3 to 25 years (mean age 13.6 years) were
studied.
Table 1 shows the main results obtained. D-dimer results
were significantly elevated in patients with HIV viral load
>1000 cp/mL. The reduction of anticoagulant activity of C
protein, S protein and antithrombin, similarly showed a
strong relation with viral replication.
Conclusion
The higher anticoagulant activity present in symptomatic
patients (CDC classification B and C) could be explained
by the treatment, and its related viral suppression, more
frequent in these subjects. No relation has been observed
regarding C reactive protein levels. These preliminary data
seem to confirm the same observation done in adult
cohorts, but further studies are necessary to correlate such
alterations with clinical events and to investigate the pro-
tective role of therapy in this particular population.
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1. Elevated levels of interleukin-6 and D-dimer are associated
with an increased risk of death in patients with HIV. Lewis
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27 (30,7%) 256 ± 169 >0.05 89,9 ± 20,4 0,02 74,4 ± 21,9 N.S. 107,2 ± 9,2 0,002 0,21 ± 0,37 >0.05.
classification 
B/C
61 (69,7%) 240 ± 170 103,1 ± 24,1 68,4 ± 20,1 116,1 ± 13,6 0,25 ± 0,35
CD4% >25 68 (77,3%) 229 ± 136 >0.05. 100,5 ± 23.2 >0.05 74.1 ± 19.5 0,001 114,6 ± 13,2 0,024 0,23 ± 0,33 >0,05
<25 20 (22,7%) 297 ± 249 94.3 ± 25,4 57.2 ± 20,0 108,9 ± 11,5 0,27 ± 0,41
HIV-RNA 
<1000
63 (71.6%) 206 ± 100 0.024 101,9 ± 26,0 0,007 75,3 ± 18,2 0.0003 115,5 ± 13,6 0,005 0,23 0,30 >0.05
(cp/mL) 
>1000
25 (28,4%) 341 ± 253 92,0 ± 14,7 57,6 ± 21,7 107,5 ± 9,2 0,27 0,47
* Mann-Whitney TestPage 2 of 2
(page number not for citation purposes)
